Literature DB >> 31843451

miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells.

Jing Xiao1, Yankun Liu2, Fuxia Wu1, Ruiyan Liu3, Yongli Xie1, Qian Yang1, Yufeng Li4, Min Liu1, Shengping Li5, Hua Tang6.   

Abstract

Emerging evidence has indicated that abnormal methylation of DNA contributes to hepatocarcinogenesis. However, the regulatory mechanisms are not well known. Here, we revealed that microRNA-639 (miR-639) expression is downregulated in liver cancer tissues and cells. The repression of miR-639 expression was attributed to hypermethylation in its promoter region, and DNA methyltransferase (DNMT3A) was found to mediate this hypermethylation. Repression of miR-639 expression promoted cell growth and migration/invasion in vitro and the growth of tumors in xenograft mouse models. Furthermore, miR-639 bound to the 3' UTR of both MYST2 and ZEB1 and suppressed their expression. MYST2 promoted the growth of liver cancer cells and ZEB1 facilitated the migration/invasion of liver cancer cells. Ectopic expression of MYST2 and ZEB1 counteracted the repression of malignancy induced by miR-639, which coincided with the reciprocal correlation between miR-639 and MYST2 and ZEB1 expression in clinical hepatocellular carcinoma (HCC) tissues. Thus, DNMT3A-mediated hypermethylation suppressed miR-639 expression, derepressing the expression of MSYT2 and ZEB1, which promoted tumorigenesis of liver cancer. These findings may shed light on the mechanism of abnormal expression of miRNAs involved in the malignancy of liver cancer and provide new biomarkers for liver cancer.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EMT; liver cancer; methylation; miRNA; proliferation; promoter

Mesh:

Substances:

Year:  2019        PMID: 31843451      PMCID: PMC7001092          DOI: 10.1016/j.ymthe.2019.11.021

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  43 in total

Review 1.  Functions of myst family histone acetyltransferases and their link to disease.

Authors:  Nikita Avvakumov; Jacques Côté
Journal:  Subcell Biochem       Date:  2007

2.  MicroRNA-10a is involved in the metastatic process by regulating Eph tyrosine kinase receptor A4-mediated epithelial-mesenchymal transition and adhesion in hepatoma cells.

Authors:  Yan Yan; Yue-Chen Luo; Hai-Ying Wan; Jun Wang; Pei-Pei Zhang; Min Liu; Xin Li; Shengping Li; Hua Tang
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

3.  DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.

Authors:  M Okano; D W Bell; D A Haber; E Li
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

Review 4.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

5.  MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.

Authors:  Jun-Nian Zhou; Quan Zeng; Hai-Yang Wang; Biao Zhang; Si-Ting Li; Xue Nan; Ning Cao; Chun-Jiang Fu; Xin-Long Yan; Ya-Li Jia; Jing-Xue Wang; Ai-Hua Zhao; Zhi-Wei Li; Yan-Hua Li; Xiao-Yan Xie; Xiao-Mei Zhang; Yan Dong; Ying-Chen Xu; Li-Juan He; Wen Yue; Xue-Tao Pei
Journal:  Hepatology       Date:  2015-07-03       Impact factor: 17.425

6.  miR-221 overexpression contributes to liver tumorigenesis.

Authors:  Pascal Pineau; Stefano Volinia; Katherine McJunkin; Agnès Marchio; Carlo Battiston; Benoît Terris; Vincenzo Mazzaferro; Scott W Lowe; Carlo M Croce; Anne Dejean
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-15       Impact factor: 11.205

7.  miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma.

Authors:  Mayuko Furuta; Ken-ich Kozaki; Shinji Tanaka; Shigeki Arii; Issei Imoto; Johji Inazawa
Journal:  Carcinogenesis       Date:  2009-10-20       Impact factor: 4.944

Review 8.  The role of microRNAs in liver cancer progression.

Authors:  S Huang; X He
Journal:  Br J Cancer       Date:  2010-11-23       Impact factor: 7.640

Review 9.  Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma.

Authors:  Eric Hervouet; Paul Peixoto; Régis Delage-Mourroux; Michaël Boyer-Guittaut; Pierre-François Cartron
Journal:  Clin Epigenetics       Date:  2018-02-09       Impact factor: 6.551

10.  miR-10a suppresses colorectal cancer metastasis by modulating the epithelial-to-mesenchymal transition and anoikis.

Authors:  Yankun Liu; Yingnan Zhang; Haidong Wu; Yufeng Li; Yi Zhang; Min Liu; Xin Li; Hua Tang
Journal:  Cell Death Dis       Date:  2017-04-06       Impact factor: 8.469

View more
  8 in total

1.  Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9.

Authors:  Lu Liang; Wen-Yan Xu; Ao Shen; Hui-Yu Cen; Zhi-Jun Chen; Lin Tan; Ling-Min Zhang; Yu Zhang; Ji-Jun Fu; Ai-Ping Qin; Xue-Ping Lei; Song-Pei Li; Yu-Yan Qin; Jiong-Hua Huang; Xi-Yong Yu
Journal:  Acta Pharmacol Sin       Date:  2022-04-06       Impact factor: 6.150

Review 2.  Targeting Epigenetic Modifiers of Tumor Plasticity and Cancer Stem Cell Behavior.

Authors:  Vigneshwari Easwar Kumar; Roshni Nambiar; Cristabelle De Souza; Audrey Nguyen; Jeremy Chien; Kit S Lam
Journal:  Cells       Date:  2022-04-21       Impact factor: 7.666

3.  miR-26a-5p Suppresses Wnt/β-Catenin Signaling Pathway by Inhibiting DNMT3A-Mediated SFRP1 Methylation and Inhibits Cancer Stem Cell-Like Properties of NSCLC.

Authors:  Jie Yu; Zhe Ge; Shunqiong Chen; Shaoying Li; Xin Zhang; Jie Hu; Wei Guo; Yan Wang
Journal:  Dis Markers       Date:  2022-07-11       Impact factor: 3.464

4.  Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma.

Authors:  Lijuan Cui; Huan Xue; Zhitong Wen; Zhihong Lu; Yunfeng Liu; Yi Zhang
Journal:  Aging (Albany NY)       Date:  2020-11-12       Impact factor: 5.682

5.  Screening of Methylation Gene Sites as Prognostic Signature in Lung Adenocarcinoma.

Authors:  Min Dong; Zengli Yang; Xingfang Li; Zhenxiang Zhang; Ankang Yin
Journal:  Yonsei Med J       Date:  2020-12       Impact factor: 2.759

6.  CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Yonglin Yi; Zhengang Qiu; Zifu Yao; Anqi Lin; Yimin Qin; Ruizhan Sha; Ting Wei; Yanru Wang; Quan Cheng; Jian Zhang; Peng Luo; Weitao Shen
Journal:  Front Cell Dev Biol       Date:  2022-01-11

7.  The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy.

Authors:  Lu Liang; Huiyu Cen; Jionghua Huang; Aiping Qin; Wenyan Xu; Siran Wang; Zhijun Chen; Lin Tan; Qiqi Zhang; Xiyong Yu; Xin Yang; Lingmin Zhang
Journal:  Mol Cancer       Date:  2022-09-28       Impact factor: 41.444

8.  MiR-9-1 Suppresses Cell Proliferation and Promotes Apoptosis by Targeting UHRF1 in Lung Cancer.

Authors:  Cheng-You Jia; Wei Xiang; Ji-Bin Liu; Geng-Xi Jiang; Feng Sun; Jian-Jun Wu; Xiao-Li Yang; Rui Xin; Yi Shi; Dan-Dan Zhang; Wen Li; Zavuga Zuberi; Jie Zhang; Gai-Xia Lu; Hui-Min Wang; Pei-Yao Wang; Fei Yu; Zhong-Wei Lv; Yu-Shui Ma; Da Fu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.